Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Trained on Recursion’s BioHive-2 and accelerated by NVIDIA, the model achieves near-FEP accuracy at speeds up to 1,000× faster, marking one of the most significant advances yet in AI-enabled drug ...

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

Recursion uses a data-driven approach to drug discovery, launching four clinical trials in 2021 and planning a fifth in oncology. Click here to read more.

"Our partnership with Recursion underscores the transformative potential of real-world data in driving smarter clinical trials," said Andrew Kress, CEO of HealthVerity.

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology ...

HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding ...